Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 255

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Open access
Nakamura, Yoshiaki, Watanabe, Jun, Akazawa, Naoya, Hirata, Keiji, Kataoka, Kozo, Yokota, Mitsuru, Kato, Kentaro, Kotaka, Masahito, Kagawa, Yoshinori, Yeh, Kun-Huei, Mishima, Saori, Yukami, Hiroki, Ando, Koji, Miyo, Masaaki, Misumi, Toshihiro, Yamazaki, Kentaro, Ebi, Hiromichi, Okita, Kenji, Hamabe, Atsushi, Sokuoka, Hiroki, Kobayashi, Satoshi, Laliotis, George, Aushev, Vasily N., Sharma, Shruti, Jurdi, Adham, Liu, Minetta C., Aleshin, Alexey, Rabinowitz, Matthew, Bando, Hideaki, Taniguchi, Hiroya, Takemasa, Ichiro, Kato, Takeshi, Kotani, Daisuke, Mori, Masaki, Yoshino, Takayuki, Oki, Eiji · 2024 · Nature Medicine

Abstract

The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II–III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P < 0.0001) and overall survival (OS; HR: 9.68, P < 0.0001). In patients who experienced recurrence, ctDNA positivity correlated with shorter OS (HR: 2.71, P < 0.0001). The significantly shorter DFS in MRD-positive patients was consistent across actionable biomarker subsets. Sustained ctDNA clearance in response to ACT was an indicator of favorable DFS and OS compared to transient clearance (24-month DFS: 89.0% versus 3.3%; 24-month OS: 100.0% versus 82.3%). True spontaneous clearance rate with no clinical recurrence was 1.9% (2/105). Overall, our findings provide evidence for the utility of ctDNA monitoring for post-resection recurrence and mortality risk stratification that could be used for guiding adjuvant therapy. In a large cohort with a 23-month median follow-up of the CIRCULATE-Japan GALAXY observational study, ctDNA-based detection of molecular residual disease was predictive of survival outcomes and benefit of adjuvant chemotherapy in patients with resectable colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03254-6

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Metadata

Authors
Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K.-H., Mishima, S., Yukami, H., Ando, K., Miyo, M., Misumi, T., Yamazaki, K., Ebi, H., Okita, K., Hamabe, A., Sokuoka, H., Kobayashi, S., Laliotis, G., Aushev, V. N., Sharma, S., Jurdi, A., Liu, M. C., Aleshin, A., Rabinowitz, M., Bando, H., Taniguchi, H., Takemasa, I., Kato, T., Kotani, D., Mori, M., Yoshino, T., & Oki, E.
Venue
Nature Medicine
Published
2024-09-16
Volume
30
Issue
11
Pages
3272-3283
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4402582106
Cited by
255
References
19
FWCI
39.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ctDNA-based molecular residual disease and survival in resectable colorectal cancer. https://app.cochat.ai/papers/10.1038/s41591-024-03254-6
The paper
Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K.-H., Mishima, S., Yukami, H., Ando, K., Miyo, M., Misumi, T., Yamazaki, K., Ebi, H., Okita, K., Hamabe, A., . . . Oki, E. (2024). ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature Medicine. https://doi.org/10.1038/s41591-024-03254-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.